|Bid||175.50 x 800|
|Ask||176.00 x 900|
|Day's range||173.59 - 183.68|
|52-week range||115.03 - 321.30|
|Beta (5Y monthly)||1.73|
|PE ratio (TTM)||6.10|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Much of the social and economic post-pandemic recovery is accredited to Covid-19 vaccine makers Pfizer (PFE) and Moderna (MRNA). Investors may be wondering if these stocks will continue to be strong investments going into 2023.
(Reuters) -Pfizer Inc and its German partner, BioNTech SE, fired back at Moderna Inc on Monday in a patent lawsuit over their rival COVID-19 vaccines, seeking dismissal of the lawsuit in Boston federal court and an order that Moderna's patents are invalid and not infringed. Moderna first sued Pfizer in August, accusing the company of violating its rights in three patents related to innovations that Cambridge, Massachusetts-based Moderna said it pioneered before the COVID-19 pandemic. Moderna has also filed a related lawsuit against Pfizer and BioNTech in Germany.
We asked our freelance writers to reveal the top growth shares they’d buy in December, which included a rare double nomination for one stock... The post Best British growth stocks to buy for December appeared first on The Motley Fool UK.